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ABSTRACT
Objective: The aim of this study is to evaluate the pattern of prescription and utilization of antidepressants (ADs) for various non-psychiatric 
indications in department of general medicine, cardiology, surgery, gynecology, and orthopaedic of a tertiary care teaching hospital.
Methods: A prospective cross-sectional unicentric drug utilization study of inpatients was carried out in a 450 bedded tertiary care hospital. The 
study included 200 subjects admitted for both psychiatric and non-psychiatric illness. Pediatric patients and those with a length of stay <48 h were 
excluded from the study.
Results: Prescriptions of 200 patients were studied in which 55% were males and 45% were females. The most widely prescribed drug is alprazolam 
comprising 50% of the total drug consumption and is followed by clonazepam (19.5%), amitriptyline (13.5%), diazepam (9.5%), escitalopram 
(3.5%), lorazepam (3%), and zolpidem (0.5%). About 36% of the drugs were prescribed in the general medicine department, and 27.5% of the 
prescriptions were from the cardiology department. Prescriptions from surgery, orthopedics, and gynecology were 16%, 11.5%, and 9% of the total, 
respectively.
Conclusion: ADs were found to be potentially useful for non-psychiatric indications such as peripheral and diabetic neuropathy, gastroenterological 
conditions, and urological conditions. No benefit was observed in insomnia and musculoskeletal conditions except for fibromyalgia. ADs were also 
found to improve the treatment outcome and quality of life of patients having comorbid psychiatric conditions being treated for non-psychiatric 
disorders.
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INTRODUCTION
Antidepressants (ADs) are the widely prescribed medication among 
the general population. Prevalence of their 1 year consumption ranges 
from 6% to 10% [1]. ADs are mainly used for the management of 
major depressive episodes and anxiety [2]. Between 1980 and 2008, 
their utilization has risen by sevenfold in France, from €84 million 
to €525 million per year [3]. Selective serotonin reuptake inhibitors 
(SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) topped 
the chart of drug sales worldwide. ADs are the third most consumed 
medication in the United States of America [4]. Alarming surge in the 
utilization of these agents is a source of concern for economists although 
the exact reason behind this trend remains unknown [5,6]. Polypharmacy 
in geriatrics also pose a major concern, and some individual-based 
studies point out that amitriptyline and alprazolam are widely used as 
sedatives in the elderly despite of their strong anti-cholinergic action [7]. 
According to various studies, there are two probable explanations; the 
first is over-prescription for psychiatric disorders. Evidence suggests 
that ADs are not capable of producing dramatic changes in moderate-to-
severe episodes; however, they are life changers in mild depression [8,9]. 
Sometimes they are stopped too early or given too long. The second 
reason is the prescription of them for “non-psychiatric conditions.” 
Evaluating their potential merits are demanding, as they are extensively 
used for numerous non-psychiatric illness including gastroenterological 
and neurological an urological diseases.
Emerging evidence substantiates that ADs are more often than not 
prescribed for health disorders outside the field of psychiatry [10]. 
This rate, according to various observational studies, ranges from 25% 
to 60%. Research has pointed out that, apart from non-psychiatric 
conditions, these drugs are also given for a number of off-label 
uses. Mostly, personal feelings of health practitioners outweigh ADs 
prescription rather than relevant scientific evidence.
The aim of this study is to review evidence from various guidelines of 
AD prescription for non-psychiatric conditions in a tertiary care setting. 
The rationale behind this study is to make the health-care team aware 
about the unanticipated consequences from the overuse of AD class of 
medications and monitor their use in the hospital settings.
METHODS
This was an observational, cross-sectional study conducted in a tertiary 
care teaching hospital, India. The study was carried out for a period 
of 6-month after approval of the Institutional Ethics Committee of 
Hospital (IHEC, SJH). The protocol was approved by the committee 
with the approval number SJPCEC/P25/PP/2014/033 and the hospital 
approval number SJCP/DIR/A.19/2015-2016. A total of 200 patients 
were enrolled in this research.
Inclusion criteria
The following criteria were included in the study:
•	 All	inpatients	in	cardiology,	general	medicine,	orthopedics,	surgery,	





The following criteria were excluded from the study:
•	 Pediatric	patients
•	 Patients	with	a	length	of	stay	>48	h.
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Data of patients meeting the inclusion criteria were promptly recorded 
in the predesigned data pro forma by attending the daily ward rounds, 
reviewing patient medications, collecting relevant details from patients 
and carrying out the AD utilization review. Prescriptions obtained were 
evaluated for demographic data using the WHO core drug prescription 
indicators.
RESULTS
A prospective observational study was carried out for a period of 
6 months in a 450 bedded tertiary care hospital to evaluate the drug 
utilization pattern of ADs in non-psychiatric departments. A total 
of 200 patients from five wards were enrolled in the study based on 
inclusion criteria. The results obtained were as follows;
Patients	 of	 age	 group	 25–75	 years	 were	 selected,	 and	 the	 majority	
belongs	to	the	group	of	65–75	years	(33%)	of	which	55%	were	males	
and 45% were females.
Table 1 presents that, among various ADs prescribed, alprazolam pecked 
the list (50.5%), followed by clonazepam (19.5%), amitriptyline (13.5%), 
diazepam (9.5%), escitalopram (3.5%), and lorazepam (3%), and the 
least prescribed drug during the study period was zolpidem (0.5%).
Table 2 shows that out of all cases (n=200) AD use was the maximum in 
the department of general medicine (27.5%), and the least was in the 
gynecology department (9%).
In the cardiology department, the most prescribed drug was 
alprazolam 52% (n=29) and the least was escitalopram 3.6% (n=20) 
while in orthopedics amitriptyline 56.5% (n=13) was the topper and 
clonazepam was given the least 8.6% (n=2). Alprazolam was the most 
utilized ADs in the department of general medicine comprising 45% 
of prescription (n=32). Diazepam and zolpidem shared the lowest 
position with 1.3% each (n=1). In the surgery ward, 90.6% of total 
prescription was for alprazolam (n-29) and the amitriptyline was the 
least prescribed one. Diazepam was the only (n=18) AD used in the 
obstetrics and the gynecology department.
Fig. 1 shows the percentage distribution of antidepressants for the 
management of psychiatric illness in various departments. Out of 
samples (n=23), about 4% (n=8) of drug usage in cardiac patients 
were for the management of underlying psychiatric conditions. Similar 
prescribing pattern was found in the general medicine ward 5% (n=10) 
and orthopedic ward 2.5% (n=5).
Fig. 2 shows that about 177 cases for non-psychiatric illness were 
studied (n=177), 20% of antidepressant were used for treating primary 
insomnia (n=40), followed by pre-operative and post-operative pain 
management with 13.5% (n=27) and 13% (n=26), respectively, followed 
by diabetic and peripheral neuropathy 12.5% (n=25), inflammatory 
bowel syndrome 5%, overactive bladder 5%, urinary incontinence 4%, 
and panhypopituitarism 3%.
Depression is one of the most prevalent risk factors for the development 
and progression of coronary artery disease, cardiovascular disease, 
diabetes mellitus, etc. Apart from its indicated use, ADs may also be 
given to improve the treatment outcome and patients quality of life. 
Distribution of AD based on a comorbid psychiatric condition in non-
psychiatric departments was analyzed.
DISCUSSION
Drug utilization studies (DUS) are a tool for assessing the prescribing, 
dispensing, and distribution of drugs. DUS is mainly intended to 
facilitate rational use of medicines [11].
ADs are drugs implied in the treatment of depression and to prevent 
its reoccurrence. Apart from their primary indications, they are widely 
being used for various non-psychiatric conditions. This study was 
designed to evaluate the need of ADs medication for these indications 
with evidence for its benefit in every category. In this study, a total of 
200 prescriptions were analyzed, of which, 109 (55%) were males 
and 91(45%) were females which are in concordance with the study 
conducted by Kumar et al. [12].
Amitriptyline is the only AD used in prophylaxis of vascular headaches 
(n=5). Increased use of amitriptyline may be because the current 
recommendations consider it as level IA evidence drug, with a 

















Fig. 1: Percentage distribution based on psychiatric indication
Fig. 2: Percentage distribution based on non-psychiatric indication
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therapeutic dose ranging from 30 to 150 mg/day. ADs were also 
beneficial in gastroenterological conditions like IBS. Tricyclic ADs 
(TCA) could be used as a second line agent and SSRI as third-line agent. 
It aids to control the symptoms of IBS such as burping and persistent 
abdominal pain. We have found that low dose amitriptyline was rarely 
used	in	the	treatment	of	GERD	as	that	demonstrated	by	Morgan	et al. 
that the doses for the pain-relieving and neuromodulatory effects of 
the drug were below the minimum therapeutic dose range [13] As the 
disease increase in severity, higher doses may be needed to modify the 
deteriorating gastrointestinal and bowel functions.
ADs were used for fibromyalgia in 1.5% of cases in our study as 
substantiated by Hauser et al. in the study “treatment of fibromyalgia 
syndrome with AD” a meta-analysis in which AD medications can help 
with the remission of pain, lethargy, insomnia, and improvement of 
health-related quality of life in patients with fibromyalgia [14].
ADs should be used as first-line agent for peripheral neuropathy and 
diabetic neuropathy which results in the frequently disabling pain. 
ADs are highly beneficial for neuropathic pain due to its analgesic 
actions. A prescription pattern study by Jena et al. found out that TCA 
and SNRI need to be given for neuropathic pain instead of adding 
nonsteroidal anti-inflammatory drugs and opioids [15]. TCAs are 
most effective and are considered to as first-line agents while SNRIs 
are second-line agents for the treatment of neuropathic pain. We 
have found 37 cases of patients being treated with ADs in various 
departments for pain in which 12.5% is for peripheral and diabetic 
neuropathy and 6% for other pain conditions wherein TCA were the 
most deployed drug class. A study by pinky Dharmshaktu et al. reveals 
that TCA was the gold standard drug for the control of persistent 
neuropathic pain [16].
In orthopedics patients, alprazolam is highly potent in decreasing 
the post-operative analgesic use, and it also improves knee functions 
by reducing pain threshold particularly in patients undergoing TKR 
and improves quality of life for those with concurrent depression. We 
havefound 21.7% cases with concomitant mental status alterations 
in this department which is in contrast to the 56% of cases in a study 
by Yilmaz et al. [17]. The difference may be attributed to a probably 
higher level of patient mental status assessment done in the latter in 
comparison to a tertiary care hospital with limited prospects.
ADs, especially SSRI contribute to hyponatremia. One such case of a 
patient diagnosed with sodium depletion with relevant laboratory 
evidence and given the drug escitalopram was found during the 
research	which	can	be	substantiated	by	the	observations	of	Grover	et al., 
revealing a higher incidence of SSRI associated electrolyte abnormality 
drawing a conclusion that TCA can be a more safer choice [18].
CONCLUSION
By analyzing the data collected from the study, two patterns of 
prescribing anti-depressants were found in non-psychiatric wards; 
prescribing for treating non-psychiatric conditions such as neuropathy, 
IBS, and urological conditions and prescribing to treat comorbid 
psychiatric illness which may pose a risk for the non-psychiatric 
condition for which the patient is being treated.
ADs were found to be highly beneficial in the treatment of pain and 
neuropathic conditions. Unnecessarily prescribing and consuming of 
ADs may lead to addiction. The certain patient tends to take the drug 
even after the recommended course got over. ADs are drugs which have 
to be prescribed if and only if, it is indicated and necessary. Evidence 
against prescribing them was also found. The overall incongruity of the 
gathered data impeded the critical evaluation of the evidence. It is also 
crucial to spotlight the difference between appraising the scientifically 
acquainted effects of an AD for a specific condition and their potential 
advantages at the right dose and right time for a specific patient despite 
a lower level of proof.
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